Platelet-mediated pseudovon Willebrand disease
Platelet-type pseudo-von Willebrand disease is characterized by varying degrees of bleeding symptoms and a decrease in plasma high molecular weight vWF polymers. Since this disease has some characteristics of von Willebrand disease (vWD), but its defect lies in GPⅠb/Ⅸ, this disease is also called pseudo-vWD or platelet-type vWD.
-
Site of disease:
Blood vessels -
Infectious :
Not contagious -
Frequent population:
All groups -
Related symptoms:
Skin and mucous membrane bleeding Gum bleeding Bleeding after tooth extraction Thrombocytopenia Skin and mucous membrane bleeding -
Concurrent disease:
Related Drugs
Tranexamic Acid Injection
Indication: 1. This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product is generally not used before heparinization; 2. It is used for traumatic or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands; 3. It is used as an antagonist of tissue plasminogen activator (t-PA), streptokinase, and urokinase; 4. It is used for fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism, as well as menorrhagia caused by pathological local increased fibrinolysis in the uterine cavity; 5. It is used for mild bleeding caused by central nervous system diseases, such as subarachnoid hemorrhage and intracranial aneurysm bleeding. The use of this product for hemostasis is superior to other anti-fibrotic drugs.
Tranexamic Acid Injection
Indication: 1. This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product is generally not used before heparinization; 2. It is used for traumatic or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands; 3. It is used as an antagonist of tissue plasminogen activator (t-PA), streptokinase, and urokinase; 4. It is used for fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism, as well as menorrhagia caused by pathological local increased fibrinolysis in the uterine cavity; 5. It is used for mild bleeding caused by central nervous system diseases, such as subarachnoid hemorrhage and intracranial aneurysm bleeding. The use of this product for hemostasis is superior to other anti-fibrotic drugs.
Manufacturer:
Hunan Dongting Pharmaceutical Co., Ltd.
Related Ingredients